A U.S. unit of British drug company BTG Plc pleaded guilty on Monday to improperly marketing its embolic device LC Bead, and will pay about $36 million to resolve its criminal and civil liability ...

Embolization is a minimally invasive procedure that blocks blood vessels in order to impede blood flow and enable the shrinkage of hypervascularized tumors. It's a common approach used in tough-to ...

Inc. subsidiary has reached a settlement with the US government in relation to the Department of Justice's investigation of the marketing of LC Bead®. The investigation focused on the period pre ...

The New York-based medical device maker will pay $11.5 million over allegations it was the distributor for Biocompatibles Plc of the LC Bead for use as a drug-delivery device in combination with ...

in a US$4.5m deal with Biocure Inc. The patents - over DC Bead, LC Bead and Bead Block – have been licensed from Biocure since 2002, with Biocompatible paying a 5% royalty from sales until 2011.